The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study
Article in Journal of the Canadian Association of Gastroenterology (March 2024)
The most recent citing publications are shown below. View all 42 publications that cite this research output on Dimensions.
Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Article in Medicina (January 2024)
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Article in Crohn's & Colitis 360 (January 2024)